Venture capital is going through a wrenching and potentially permanent transformation. The losses of the past decade and the sluggish economy have taken a toll, forcing some VCs to virtually halt new investment to focus on their existing portfolios, while others are gravitating toward safer later-stage deals or making smaller, earlier-stage bets. Estimates are that one-third to as many as one-half of VC firms could be slowly going out of business. Yet amidst it all, software, wireless, and life sciences businesses still need significant, multi-year support from venture capital to truly execute on their business plans and potentially become billion-dollar companies.
Or do they? How are Seattle-area entrepreneurs—and angel investors—seeking to adapt to the new world where venture capital is scarce but innovation is marching on? We at Xconomy have assembled some outspoken leaders from the worlds of venture capital, angel investment, and startups to talk about how financing schemes and power dynamics are changing in the complicated relationship between entrepreneurs and financiers—and what it all means for the future of startups and venture capital across all sectors of innovation, from high-tech to biotech to cleantech. Xconomy’s national life sciences and technology editors, Luke Timmerman and Greg Huang, will ask the hard questions of these speakers and invite you to join the conversation.
Bob Nelsen, Managing Director, Arch Venture Partners
Tom Alberg, Managing Director, Madrona Venture Group
Martin Tobias, Founder and CEO, Tippr
Christopher Henney, Chairman, Oncothyreon; Co-founder Immunex, Icos, Dendreon
Registration: 5:15 – 6:00 pm
Program: 6:00 – 7:00 pm
Networking reception: 7:00 – 8:00 pm
Early Bird Rate (ends September 29): $95
Regular Registration: $150
Walk-in Registration: $195
Student Registration: $30
Tickets are transferable but not refundable.
To inquire about press registration, e-mail email@example.com.